{
  "scenario_id": "pharma_clinical_trial_acceleration_2025",
  "context": "Global pharmaceutical company with traditional clinical development pipeline facing pressure to accelerate time-to-market",
  "stakeholders": {
    "requester": "Head of Clinical Development",
    "approvers": [
      "Chief Medical Officer",
      "Chief Executive Officer"
    ],
    "influencers": [
      "Regulatory Affairs Director",
      "Data Science Lead",
      "Patient Advocacy Groups"
    ]
  },
  "request": {
    "amount": "$120,000,000",
    "purpose": "Implementation of AI-driven clinical trial acceleration platform including adaptive trial designs and real-time monitoring",
    "urgency": "high",
    "justification": "Industry trend toward faster drug development with potential 30% reduction in trial timelines"
  },
  "decision_process": [
    {
      "stage": "technology_evaluation",
      "duration": "4 weeks",
      "activities": [
        "AI platform vendor assessment",
        "Regulatory acceptance analysis",
        "Technical integration review"
      ],
      "outcome": "Leading AI platforms identified"
    },
    {
      "stage": "regulatory_assessment",
      "duration": "6 weeks",
      "activities": [
        "FDA guidance review",
        "Adaptive trial protocol development",
        "Ethics committee consultation"
      ],
      "outcome": "Regulatory framework established"
    },
    {
      "stage": "pilot_design",
      "duration": "5 weeks",
      "activities": [
        "Pilot trial selection",
        "Implementation timeline development",
        "Resource allocation planning"
      ],
      "outcome": "Pilot program designed for Phase II trials"
    },
    {
      "stage": "executive_approval",
      "duration": "3 weeks",
      "activities": [
        "ROI analysis presentation",
        "Risk mitigation review",
        "Leadership team approval"
      ],
      "outcome": "Approved with $80M investment"
    }
  ],
  "business_impact": {
    "expected_time_savings": "25%",
    "projected_cost_reduction": "$200,000,000",
    "risk_factors": [
      "Regulatory uncertainty with AI-driven trials",
      "Data quality and bias concerns",
      "Integration with existing systems"
    ],
    "strategic_benefits": [
      "Faster time-to-market for new drugs",
      "Improved clinical trial success rates",
      "Competitive advantage in drug development"
    ]
  }
}
